This is the authors' abstract. We don't add key points for this paper.
Despite the exceptional initial response rates with chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL), the duration of response (DOR) is short and more than half the patients relapse.1,2 Patients who fail to respond or relapse after CAR T-cell therapy have a poor prognosis, especially those who relapse within 30 days.3 Treatment options after CAR T-cell therapy are limited and persistent cytopenias can limit the use of salvage therapy or participation in clinical trials.4 In a study by Spiegel et al, 26% of the patients who progressed after CAR T-cell received supportive care whereas 74% received various therapies.5 The overall response rate (ORR) in more commonly used therapies was 29%, with only 17% of the patients achieving a complete response (CR) while median progression-free survival (PFS) and overall survival (OS) were 55 days and 180 days, respectively.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Furqan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: